ImageneBio (IMA) Short term Debt (2024)

ImageneBio's (IMA) quarterly Short term Debt came in at $7.5 million in Q4 2024.

ImageneBio (IMA) Short term Debt (2024) Analysis & Trends

ImageneBio has disclosed Short term Debt across 1 years of filings, most recently posting $7.5 million for Q4 2024.

  • Short term Debt for Q4 2024 came in at $7.5 million, changed N/A year-over-year; the trailing twelve-month figure through Dec 2024 was $7.5 million (changed N/A YoY), and the FY2024 annual result was $7.5 million, changed N/A from the prior year.
  • Short term Debt came in at $7.5 million for Q4 2024 at ImageneBio.
  • In the past five years, Short term Debt ranged from a high of $7.5 million in Q4 2024 to a low of $7.5 million in Q4 2024.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Alterity Therapeutics 925,601.88 Bn 925,601.85 Bn -
2 Belite Bio 58,560.00 Bn 58,560.00 Bn -
3 Quantum Biopharma 17,284.41 Bn 17,284.40 Bn -
4 Legend Biotech 2,809.00 Bn 2,808.71 Bn 242.10 Mn
5 Evaxion A 1,334.43 Bn 1,334.42 Bn -
6 Akari Therapeutics 1,312.27 Bn 1,312.26 Bn -
7 Psyence Biomedical 212.16 Bn 212.16 Bn -
8 Vertex Pharmaceuticals 114.83 Bn 107.58 Bn 2.59 Bn
9 Abivax 91.96 Bn 91.96 Bn -
10 ImageneBio 3.18 Mn 3.18 Mn -

Historic Data

Download Data
DateValue
Dec 31, 2024 7.50 Mn